Skip to main content

What the FDA labels say about taking them together

Haloperidol and sodium phenylbutyrate

Sodium phenylbutyrate's FDA label of July 17, 2026 names haloperidol in its drug interactions section; the haloperidol labels PlainMeds reads (2) do not name sodium phenylbutyrate. The sodium phenylbutyrate label: “DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely.”

Check it at the source: the haloperidol FDA label on DailyMed (effective April 23, 2026, PD-Rx Pharmaceuticals, Inc.); the sodium phenylbutyrate FDA label on DailyMed (effective July 17, 2026, Medunik USA).

What does the haloperidol label say about sodium phenylbutyrate?

Haloperidol's label (effective April 23, 2026) and its 1 other brand-application label do not name sodium phenylbutyrate in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Haloperidol), PD-Rx Pharmaceuticals, Inc., effective April 23, 2026 (SPL set 533b0b4c-cbd6-4ec0-a333-8b04b5b43a1d), via openFDA; the full label on DailyMed

What does the sodium phenylbutyrate label say about haloperidol?

Sodium phenylbutyrate label, drug interactions

DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely.

Source: FDA drug label (Olpruva, NDA214860), Acer Therapeutics Inc., effective December 18, 2024 (SPL set 89abc31c-43e8-4809-9eb7-172cb31a86f1), via openFDA

Source: FDA drug label (PHEBURANE), Medunik USA, effective July 17, 2026 (SPL set d15f2cbf-4d22-40b5-8ef9-16b9d323a7f9), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

41Haloperidol generic labelers
4Sodium phenylbutyrate generic labelers
HaloperidolSodium phenylbutyrate
Labeled forSchizophrenian/a
Boxed warningYesNo
Pharmacy cost (NADAC)$15.60 per mL 100 mg/mL vialn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?